This is the authors' abstract. We don't add key points for this paper.
Maleimide is a rare but powerful pharmacophore in natural products, yet its biosynthetic logic remains poorly understood. Here, we elucidate the biosynthesis of ligiamycins, bacterial decalin–amino-maleimide metabolites from Streptomyces sp. NA07271. Genetic and biochemical studies revealed an unusual dispersed PKS–NRPS pathway, in which LigO1 hydroxylates a PCP-tethered precursor, followed by LigQ-mediated Dieckmann cyclization and LigN-catalyzed Diels–Alder cyclization to construct the tetramate-containing trans-decalin scaffold. Unexpectedly, LigM catalyzes a cryptic C-2 O-methylation that is not retained in the isolated products, but instead primes the scaffold for LigO2-mediated oxidation to a highly electrophilic methoxy-maleimide species. This reactive intermediate is readily intercepted by amine nucleophiles through nonenzymatic addition–elimination, giving rise to diverse amino-maleimide congeners. These findings reveal transient methylation as a biosynthetic activation strategy, redefine the chemical end point of ligiamycin biosynthesis, and establish methoxy-maleimide as a promising reactive functional group for natural product diversification and bioconjugation.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: